<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font16 { font-size : 16; } .font17 { font-size : 17; } .font18 { font-size : 18; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">RSV </span>
   <span class="font18">respiratory </span>
   <span class="font17">infants </span>
   <span class="font16">vaccine </span>
   <span class="font16">virus </span>
   <span class="font16">syncytial </span>
   <span class="font15">[]. </span>
   <span class="font15">antibody </span>
   <span class="font15">maternal </span>
   <span class="font14">[], </span>
   <span class="font14">infection </span>
   <span class="font13">women </span>
   <span class="font13">antibodies </span>
   <span class="font13">disease </span>
   <span class="font13">immunization </span>
   <span class="font13">young </span>
   <span class="font12">neutralizing </span>
   <span class="font12">pregnant </span>
   <span class="font12">study </span>
   <span class="font12">clinical </span>
   <span class="font12">Infect </span>
   <span class="font12">development </span>
   <span class="font12">vaccines </span>
   <span class="font12">{border-style </span>
   <span class="font12">prevention </span>
   <span class="font12">protection </span>
   <span class="font12">F-protein </span>
   <span class="font12">children </span>
   <span class="font12">px;} </span>
   <span class="font11">#ffffff;} </span>
   <span class="font11">hospitalization </span>
   <span class="font11">infant </span>
   <span class="font11">associated </span>
   <span class="font11">phase </span>
   <span class="font11">Palivizumab </span>
   <span class="font11">healthy </span>
   <span class="font11">LRTI </span>
   <span class="font11">burden </span>
   <span class="font11">monoclonal </span>
   <span class="font11">months </span>
   <span class="font11">potential </span>
   <span class="font11">Dis </span>
   <span class="font11">based </span>
   <span class="font11">preterm </span>
   <span class="font11">severe </span>
   <span class="font11">active </span>
   <span class="font11">efficacy </span>
   <span class="font11">high-risk </span>
   <span class="font11">pregnancy </span>
   <span class="font11">studies </span>
   <span class="font11">antigenic </span>
   <span class="font11">birth </span>
   <span class="font11">evaluated </span>
   <span class="font11">illness </span>
   <span class="font11">lower </span>
   <span class="font11">RSV-specific </span>
   <span class="font11">administration </span>
   <span class="font11">higher </span>
   <span class="font11">impact </span>
   <span class="font11">infants. </span>
   <span class="font11">influenza </span>
   <span class="font11">sites </span>
   <span class="font11">trial </span>
   <span class="font11">vaccination </span>
   <span class="font10">DisPMCPMC </span>
   <span class="font10">RSV, </span>
   <span class="font10">acute </span>
   <span class="font10">age </span>
   <span class="font10">data </span>
   <span class="font10">high </span>
   <span class="font10">including </span>
   <span class="font10">px; </span>
   <span class="font10">rates </span>
   <span class="font10">research </span>
   <span class="font10">transfer </span>
   <span class="font10">transplacental </span>
   <span class="font10">years </span>
   <span class="font10">{font-family </span>
   <span class="font10">(RSV) </span>
   <span class="font10">(Table </span>
   <span class="font10">Clinical </span>
   <span class="font10">administered </span>
   <span class="font10">cases </span>
   <span class="font10">countries </span>
   <span class="font10">days </span>
   <span class="font10">early </span>
   <span class="font10">effective </span>
   <span class="font10">font-size </span>
   <span class="font10">global </span>
   <span class="font10">health </span>
   <span class="font10">incidence </span>
   <span class="font10">infants, </span>
   <span class="font10">infections </span>
   <span class="font10">life. </span>
   <span class="font10">low </span>
   <span class="font10">need </span>
   <span class="font10">pneumonia </span>
   <span class="font10">pre-fusion </span>
   <span class="font10">present </span>
   <span class="font10">prevent </span>
   <span class="font10">prophylaxis </span>
   <span class="font10">significant </span>
   <span class="font10">strategy </span>
   <span class="font10">target </span>
   <span class="font10">use </span>
   <span class="font10">various </span>
   <span class="font10">IgG </span>
   <span class="font10">Maternal </span>
   <span class="font10">Med </span>
   <span class="font10">Respiratory </span>
   <span class="font10">Table </span>
   <span class="font10">analysis </span>
   <span class="font10">concentrations </span>
   <span class="font10">conformation </span>
   <span class="font10">double; </span>
   <span class="font10">epidemiology </span>
   <span class="font10">gestation </span>
   <span class="font10">highly </span>
   <span class="font10">human </span>
   <span class="font10">immunogenicity </span>
   <span class="font10">immunoglobulin </span>
   <span class="font10">important </span>
   <span class="font10">life </span>
   <span class="font10">life, </span>
   <span class="font10">mortality </span>
   <span class="font10">mothers </span>
   <span class="font10">passive </span>
   <span class="font10">pre-F </span>
   <span class="font10">primary </span>
   <span class="font10">results </span>
   <span class="font10">specific </span>
   <span class="font10">symptoms </span>
   <span class="font10">viral </span>
   <span class="font10">weeks </span>
   <span class="font10">year </span>
   <span class="font10">(%CI, </span>
   <span class="font10">Elderly </span>
   <span class="font10">Elsevier </span>
   <span class="font10">Health </span>
   <span class="font10">III </span>
   <span class="font10">RSV-positive </span>
   <span class="font10">available </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">bronchiolitis </span>
   <span class="font10">care </span>
   <span class="font10">conserved </span>
   <span class="font10">correlate </span>
   <span class="font10">currently </span>
   <span class="font10">demonstrated </span>
   <span class="font10">development, </span>
   <span class="font10">diagnosis </span>
   <span class="font10">documented </span>
   <span class="font10">elicit </span>
   <span class="font10">evaluation </span>
   <span class="font10">fusion </span>
   <span class="font10">given </span>
   <span class="font10">half-life </span>
   <span class="font10">immunity </span>
   <span class="font10">implementation </span>
   <span class="font10">include </span>
   <span class="font10">likely </span>
   <span class="font10">medically </span>
   <span class="font10">nanoparticle </span>
   <span class="font10">obstetric </span>
   <span class="font10">occur </span>
   <span class="font10">outcomes </span>
   <span class="font10">overall </span>
   <span class="font10">population </span>
   <span class="font10">populations </span>
   <span class="font10">presence </span>
   <span class="font10">protein </span>
   <span class="font10">reduce </span>
   <span class="font10">responses </span>
   <span class="font10">risk </span>
   <span class="font10">solid; </span>
   <span class="font10">structure </span>
   <span class="font10">support </span>
   <span class="font10">tract </span>
   <span class="font10">trials </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">(e.g. </span>
   <span class="font10">COVID- </span>
   <span class="font10">Engl </span>
   <span class="font10">Importantly, </span>
   <span class="font10">Pre-F </span>
   <span class="font10">RSV. </span>
   <span class="font10">Site </span>
   <span class="font10">South </span>
   <span class="font10">US, </span>
   <span class="font10">Vaccines </span>
   <span class="font10">achieve </span>
   <span class="font10">adjuvanted </span>
   <span class="font10">admission </span>
   <span class="font10">adults </span>
   <span class="font10">bold </span>
   <span class="font10">cause </span>
   <span class="font10">centre </span>
   <span class="font10">children, </span>
   <span class="font10">compared </span>
   <span class="font10">conducted </span>
   <span class="font10">courier; </span>
   <span class="font10">delivery </span>
   <span class="font10">design </span>
   <span class="font10">dose </span>
   <span class="font10">duration </span>
   <span class="font10">em; </span>
   <span class="font10">estimated </span>
   <span class="font10">estimates </span>
   <span class="font10">extended </span>
   <span class="font10">fever </span>
   <span class="font10">highest </span>
   <span class="font10">hospitalized </span>
   <span class="font10">host </span>
   <span class="font10">hypoxemia </span>
   <span class="font10">immunization, </span>
   <span class="font10">income </span>
   <span class="font10">increasing </span>
   <span class="font10">later </span>
   <span class="font10">limited </span>
   <span class="font10">multiple </span>
   <span class="font10">natural </span>
   <span class="font10">neutralization </span>
   <span class="font10">novel </span>
   <span class="font10">palivizumab </span>
   <span class="font10">particularly </span>
   <span class="font10">policy </span>
   <span class="font10">product </span>
   <span class="font10">prospective </span>
   <span class="font10">pt;} </span>
   <span class="font10">receive </span>
   <span class="font10">reduction </span>
   <span class="font10">requiring </span>
   <span class="font10">resource </span>
   <span class="font10">role </span>
   <span class="font10">safe </span>
   <span class="font10">safety </span>
   <span class="font10">second </span>
   <span class="font10">shown </span>
   <span class="font10">single </span>
   <span class="font10">subsequent </span>
   <span class="font10">trimester </span>
   <span class="font10">understanding </span>
   <span class="font10">vaccinated </span>
   <span class="font10">vaccine, </span>
   <span class="font10">vaccines, </span>
   <span class="font10">viruses </span>
   <span class="font10">women, </span>
  </p>
 </body>
</html>
